| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | Jul 2, 2025 | Athira Pharma, Inc. | General Counsel and CCO | Sell | 47.5 | -8,526 | -7.08% | ✗ | $2.5K |
| Nov 18, 2024 | Jan 3, 2025 | Athira Pharma, Inc. | General Counsel and CCO | Sell | 47.5 | -4,859 | -3.37% | ✗ | $4.8K |
| May 20, 2024 | Sep 5, 2024 | Athira Pharma, Inc. | GENERAL COUNSEL | Sell | 90.0 | +17,475 | 50.72% | ✗ | $1.4K |
| May 18, 2023 | Feb 16, 2024 | Athira Pharma, Inc. | GENERAL COUNSEL | Sell | 90.0 | +15,355 | 80.41% | ✗ | $7K |
| May 18, 2023 | Jan 8, 2024 | Athira Pharma, Inc. | General Counsel | Sell | 90.0 | +15,355 | 80.41% | ✗ | $7K |
| May 18, 2022 | Jun 24, 2022 | Athira Pharma, Inc. | General Counsel | Sell | 90.0 | +10,782 | 129.67% | ✗ | $7K |